ICYMI, some of this week’s featured content includes an exclusive interview about the occupational dermatoses, and articles on 2021's breakthroughs and disappointments, the risk of psoriasis related to BMI and more.
POLL: Should iPLEDGE Program be Discontinued?
Work Smarter to Manage Occupational Dermatoses
Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.
Study: Risk of Psoriasis Related to BMI
A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.
Apremilast Use During COVID-19
A recent study investigated apremilast use for psoriasis during COVID-19 infection.
Race, Ethnicity, Culture All Affect Hair Aging
A patients’ race and cultural background may be a factor in how the hair ages, according to a study in the Journal of Clinical and Aesthetic Dermatology.
Toning and strength technologies work, according to investigators, but many in cosmetic medicine question the procedures' efficacy in their field.
Pointers with Dr Portela: Can Sleep Devices Help Your Skin?
In this week’s Pointers with Dr Portela, the 208SkinDoc goes into the science behind sleep and skin while also review 3 different sleep improvement devices.
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.
FDA Accepts NDA for Roflumilast Cream
Arcutis has announced that the FDA has accepted the New Drug Application for roflumilast cream for adults and adolescent patients with plaque psoriasis.
Challenges in Diagnosing Plaque Psoriasis
Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis
Multimodal Plan Combats Combination Rosacea
Hilary Baldwin, MD, used examples of challenging cases to show how to develop successful combination regimens.
Understanding the Psychosocial Burden of Plaque Psoriasis
Considerations for the psychological and social impact that plaque psoriasis may have on a patient.
Secukinumab Receives FDA Approval for Pediatric Patients with PsA
Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
FDA Approves Apremilast for All Psoriasis Severities
With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.
2021's Breakthroughs & Disappointments
The past year gave dermatologists ample cause for both celebration and frustration as they looked forward to new drugs, devices, and technology to optimize patient care. Here, Dermatology Times® editorial advisory board members weigh in on the good, bad, and still-TBD changes that shaped the specialty during 2021.
Meet the Aesthetic Expert with Dr. Will Kirby: Emily Kaye Perbellini, MSN, FNP-C
In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Emily Kaye Perbellini, MSN, FNP-Ca, board-certified family nurse practitioner specializing in aesthetic dermatology. They discuss how to avoid burnout, challenging patient populations, and the role allied healthcare professionals in aesthetics.
The Effect of Ceramide Products on Dry Legs
A study in the Journal of Drugs in Dermatology dove into the effect of ceramide-containing products on stratum corneum lipid levels in dry legs.
Study: Treatment of Dry Skin Using Multifunctional Moisturizer
A study in the International Journal of Cosmetic Science observed the changes in skin based on different moisturizing formulations.